Anakinra, which inhibits interleukin 1, has been demonstrated to be effective in the treatment of crystalline-induced arthritis (CIA) flares. Gout treatment guidelines prescribe it only when first-line medicines have been ruled out due to contraindications or intolerance. For a study, researchers sought to determine factors that are related to a better response to anakinra when used to treat CIA flares.
It was a medical record review research that included inpatients with acute CIA who were treated with anakinra at one tertiary facility between 2014 and 2019. (the University of Alabama at Birmingham). The primary endpoint was responsiveness to anakinra therapy, defined as a 50% drop in reported visual analog score within 48 hours of treatment beginning. In addition, demographic, clinical, and laboratory characteristics were evaluated, and components identified significant in bivariate analysis with a p value less than 0.15 were assessed for an independent relationship with the response in a multivariate logistic regression analysis.
In total, 55 admission contacts were examined. The average age was 60.1 years, with 36 (66%) men and 31 (56%) African Americans. About 28 of 49 patients (57%) met the primary end objective of response at 48 hours, whereas 52 of 55 (94.5%) reacted to anakinra during their hospital stay. Race, cause for admission related to cardiac etiologies, not having failed steroids prior to treatment of anakinra, and hospitalization within 48 hours after flare commencement was linked with the response at 48 hours. They found no significant independent connections between anakinra responsiveness and a multivariable logistic regression model.
Anakinra had a high response rate in the study. However, they were unable to uncover any characteristics that were related to a more robust, early response. Anakinra is anticipated to be similarly efficacious in various clinical settings.